Eledon Pharmaceuticals, Inc. (ELDN)
| Market Cap | 33.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.87M |
| Shares Out | 13.76M |
| EPS (ttm) | -2.44 |
| PE Ratio | n/a |
| Forward PE | 4.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 957 |
| Open | 2.45 |
| Previous Close | 2.43 |
| Day's Range | 2.40 - 2.45 |
| 52-Week Range | 2.27 - 8.49 |
| Beta | 1.93 |
| Analysts | Buy |
| Price Target | 25.91 (+979.6%) |
| Earnings Date | Aug 11, 2022 |
About ELDN
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the trea... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ELDN stock is "Buy." The 12-month stock price forecast is 25.91, which is an increase of 979.58% from the latest price.
News
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IRVINE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innov...
Penny Stocks To Buy Now? 3 To Watch This Week
Penny stocks to watch this week. The post Penny Stocks To Buy Now?
Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement,...
IRVINE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innova...
Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
Topline data for Phase 2a tegoprubart study in amyotrophic lateral sclerosis (ALS) anticipated in June 2022
Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET
Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inno...
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of inno...
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET
Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference
IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innov...
Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences
IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innov...
Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results
Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022
Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D.
Presentation to focus on potential use of AT-1501 in kidney transplantation as well as research collaboration between Eledon and CareDx to help assess the efficacy of Eledon's investigational AT-1501 fo...
Eledon Pharmaceuticals Announces Participation in November Conferences
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...
Eledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021
Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET
Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis ...
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...
Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Isle...
IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...
Eledon Pharmaceuticals to Present at Two Investor Conferences in September
IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons...
A Duo of Net Current Asset Value Stock Picks to Consider
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can get a huge return out of these stocks after the market has reasses...
Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results
Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022
Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021
Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET
Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transpl...
Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...
Eledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...
Eledon Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference
IRVINE, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons l...